- Record: found
- Abstract: found
- Article: not found
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial.
Diane M Harper
1 ,
Eduardo L Franco ,
Cosette Wheeler ,
Daron G Ferris ,
David Jenkins ,
Anne Schuind ,
Toufik Zahaf ,
Bruce Innis ,
Paulo Naud ,
Newton S De Carvalho ,
Cecilia M Roteli-Martins ,
Julio Teixeira ,
Mark M Blatter ,
Abner P Korn ,
Wim Quint ,
Gary Dubin
November 16 2004
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Vaccination against the most common oncogenic human papillomavirus (HPV) types, HPV-16 and HPV-18, could prevent development of up to 70% of cervical cancers worldwide. We did a randomised, double-blind, controlled trial to assess the efficacy, safety, and immunogenicity of a bivalent HPV-16/18 L1 virus-like particle vaccine for the prevention of incident and persistent infection with these two virus types, associated cervical cytological abnormalities, and precancerous lesions.